Pfizer stock offers 30% upside with strong non-COVID franchises, margin expansion, and pipeline potential. Click here to read ...

One drug developer could be on the cusp of AI-powered glory.

Drugmaker Pfizer has agreed to lower drug costs and invest $70 billion in U.S. manufacturing under a deal struck with the Trump administration, President Donald Trump said Tuesday.The announcement, ...

In a major departure from federal health policy, the American Academy of Pediatrics (AAP) has issued independent COVID-19 vaccine guidance that diverges from the Centers for Disease Control and ...

COVID-19 is rising in prevalence in many states nationally following the July 4 holiday week, but the role of the main therapy to treat it — the antiviral drug Paxlovid — is less clear. Research ...

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential tariff effects. Sales of ...

Paxlovid didn’t lower COVID hospital or death risk for vaccinated adults ages 65-74 It may still benefit high-risk or immunocompromised patients, experts say They say the drug’s $1,650 cost should be ...

THURSDAY, March 6, 2025 (HealthDay News) -- The antiviral drug Paxlovid may not offer much protection against COVID-related hospitalizations or deaths for vaccinated older adults after all. Research ...

Patients are reporting difficulties accessing the anti-COVID drug Paxlovid this winter, even as the coronavirus causing the infectious disease reaches levels not seen in months. Angela Carpio couldn’t ...